Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$0.12.

  • Rani Therapeutics Holdings' EPS (Basic) rose 5000.0% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.79, marking a year-over-year increase of 2547.17%. This contributed to the annual value of -$1987.1 for FY2024, which is 14930427.34% down from last year.
  • Per Rani Therapeutics Holdings' latest filing, its EPS (Basic) stood at -$0.12 for Q3 2025, which was up 5000.0% from -$0.18 recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' EPS (Basic) peaked at $0.33 during Q3 2022, and registered a low of -$552.11 during Q4 2024.
  • Its 5-year average for EPS (Basic) is -$30.92, with a median of -$0.25 in 2024.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' EPS (Basic) skyrocketed by 36504.73% in 2022, and later plummeted by 20438668.92% in 2024.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' EPS (Basic) stood at -$0.27 in 2021, then plummeted by 718.52% to -$2.21 in 2022, then surged by 87.78% to -$0.27 in 2023, then crashed by 204386.69% to -$552.11 in 2024, then soared by 99.98% to -$0.12 in 2025.
  • Its EPS (Basic) was -$0.12 in Q3 2025, compared to -$0.18 in Q2 2025 and -$0.22 in Q1 2025.